文献速递细菌感染、耐药与抗菌药物

EUCAST头孢洛林折点变更对MRSA敏感性影响

Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
PubMed 文献 · Clin Microbiol Infect · 2019-04-10

该研究比较EUCAST第7.1版(2017年3月)与第8.0版(2018年1月)头孢洛林折点对复杂性皮肤软组织感染患者分离的MRSA菌株的耐药解读差异。2015至2016年共收集9559株金黄色葡萄球菌,其中5566株(58.2%)为MRSA;按第7.1版折点4.5%(250/5566)的MRSA对头孢洛林耐药,按第8.0版折点4.2%(235/5566)为中介、0.3%(15/5566)为耐药。结论为应用第8.0版折点后,多数原判耐药的MRSA菌株现归为中介,MRSA对头孢洛林耐药现已罕见。

要点

  • EUCAST第8.0版折点将多数原判头孢洛林耐药的MRSA重新归类为中介。
  • 应用第8.0版折点后MRSA对头孢洛林耐药率仅0.3%(15/5566)。
  • 判读MRSA头孢洛林药敏时需注意所用EUCAST折点版本差异。

核心结论

  • 应用EUCAST第8.0版折点后,多数原判头孢洛林耐药的MRSA菌株归为中介,MRSA对头孢洛林耐药现已罕见。

研究设计与样本

  • 参与中心位于非洲、亚洲、欧洲、大洋洲和南美洲,菌株来自复杂性皮肤软组织感染患者并从皮肤来源培养。
  • 当地用苯唑西林法确认金黄色葡萄球菌甲氧西林耐药,中央实验室用CLSI肉汤微量稀释法测定头孢洛林MIC。
  • 2015至2016年共收集9559株金黄色葡萄球菌,其中5566株(58.2%)为MRSA。
  • 分别用EUCAST第7.1版(2017年3月)与第8.0版(2018年1月)折点解读MIC数据。

主要发现

  • MRSA率最低为亚洲56.5%(705/1247),最高为大洋洲62.7%(299/477)。
  • 按第7.1版折点,4.5%(250/5566)的MRSA对头孢洛林耐药。
  • 按第8.0版折点,4.2%(235/5566)的MRSA为中介,0.3%(15/5566)为耐药。

关键数值与推荐

  • EUCAST第7.1版(2017年3月):MRSA头孢洛林耐药4.5%(250/5566)。
  • EUCAST第8.0版(2018年1月):MRSA头孢洛林中介4.2%(235/5566)、耐药0.3%(15/5566)。

临床怎么用

  • 解读MRSA对头孢洛林药敏时应明确所用EUCAST折点版本,避免将中介误判为耐药。
  • 按第8.0版折点,MRSA对头孢洛林耐药罕见,多数原耐药株应报告为中介。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In 2018, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) introduced an intermediate breakpoint for ceftaroline against Staphylococcus aureus. The objective of this study was to compare data on resistance to ceftaroline among methicillin-resistant S. aureus (MRSA) isolates using versions 7.1 (March 2017) and 8.0 (January 2018) of the EUCAST breakpoints. METHODS: Participating centers were located in Africa, Asia, Europe, Oceania and South America. Isolates were collected from patients with complicated skin and soft-tissue infections and were cultured from integumentary sources. Methicillin resistance among S. aureus was confirmed locally using the oxacillin method. The CLSI broth microdilution method was used to measure ceftaroline MICs at the central laboratory. Versions 7.1 and 8.0 of the EUCAST breakpoints were used to interpret MIC data. RESULTS: Between 2015 and 2016, 9559 isolates of S. aureus were collected, of which 5566 (58.2%) isolates were MRSA. Overall, the lowest rate of MRSA was in Asia (56.5%; 705/1247) and the highest rate was in Oceania (62.7%; 299/477). Using version 7.1 of the EUCAST breakpoints, 4.5% (250/5566) of all MRSA isolates were resistant to ceftaroline and when version 8.0 of the breakpoints was applied, 4.2% (235/5566) of MRSA were in the intermediate category and 0.3% (15/5566) of all isolates were considered resistant. CONCLUSIONS: By applying version 8.0 of the EUCAST breakpoints, the majority of MRSA isolates that were resistant are now in the intermediate category for ceftaroline. Ceftaroline resistance among MRSA now appears rare.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Urbán E, Stone GG. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections. Clin Microbiol Infect. 2019. PMID: 30980925. doi:10.1016/j.cmi.2019.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。